論文原著

英　文

• Maeda E, Ishihara O, Tomio J, Sato A, Terada Y, Kobayashi Y, Murata K.
  Cesarean section rates and local resources for perinatal care in Japan: A nationwide ecological study using the national database of health insurance claims.
  J Obstet Gynaecol Res. 2017 Nov 2. doi: 10.1111/jog.13518. [Epub ahead of print] 
• Irahara M, Kuwahara A, Iwasa T, Ishikawa T, Ishihara O, Kugu K, Sawa R, Banno K, Saito H.
  Assisted reproductive technology in Japan: a summary report of 1992-2014 by the ethics committee, Japan Society of Obstetrics and Gynecology.
  Reprod Med Biol. 16(2):126-132, 2017 
• Matsuzaki T, Douchi T, Oki T, Ishihara O, Okagaki R, Kajihara T, Tamura M, Kotsuji F, Tajima K, Kawano M, Ishizuka B, Irahara M.
  Weight reduction using a formula diet recovers menstruation in obese patients with an ovulatory disorder.
  Reprod Med Biol. 16(3):268-275, 2017 
• Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.
  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
  Lancet Oncol. 18(9): 1274-84, 2017
• Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O’Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS.
  Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
  Lancet Oncol. 18(6): 779-91, 2017
• Samura O, Sekizawa A, Suzumori N, Sasaki A, Wada S, Hamanoue H, Hirahara F, Sawai H, Nakamura H, Yamada T, Miura K, Masuzaki H, Nakayama S, Okai T, Kamei Y, Namba A, Murotsuki J, Tanemoto T, Fukushima A, Haino K, Tairaku S, Matsubara K, Maeda K, Kaji T, Ogawa M, Osada H, Nishizawa H, Okamoto Y, Kanagawa T, Kakigano A, Kitagawa M, Ogawa M, Izumi S, Katagiri Y, Takeshita N, Kasai Y, Naruse K, Neki R, Masuyama H, Hyodo M, Kawano Y, Ohba T, Ichizuka K, Kido Y, Fukao T, Miharu N, Nagamatsu T, Watanabe A, Hamajima N, Hirose M, Sanui A, Shirato N, Yotsumoto J, Nishiyama M, Hirose T, Sago H.
  Current status of non-invasive prenatal testing in Japan.
  J Obstet Gynaecol Res. 43(8): 1245-55, 2017
• Hasegawa K, Kagabu M, Mizuno M, Oda K, Aoki D, Mabuchi S, Kamiura S, Yamaguchi S, Aoki Y, Saito T, Yunokawa M, Takehara K, Okamoto A, Ochiai K, Kimura T.
  Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
  Invest New Drugs. 2017 Dec;35(6):800-812. doi: 10.1007/s10637-017-0504-6. Epub 2017 Sep 2.
• Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K.
  The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.
  Oncoimmunology. 2017 Jun 16;6(8):e1338996. doi: 10.1080/2162402X.2017.1338996. eCollection 2017.
• Sakaki M, Yasuda M, Yano M, Goto Y, Nakamura M, Kayano H, Hasegawa K.
  The prognostic significance of tumor lymphangiogenesis and lymphatic vessel density in endometrioid carcinoma of the uterine corpus.
  Oncol Lett. 14(5): 5313-18, 2017
• Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MMK, Ueland FR, Kelley JL, Roman LD.
  Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
  Gynecol Oncol. 147(3): 565-71, 2017
• Matsuo K, Johnson MS, Im DD, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Klobocista MM, Hasegawa K, Ueda Y, Shida M, Baba T, Satoh S, Yokoyama T, Machida H, Ikeda Y, Adachi S, Miyake TM, Iwasaki K, Yanai S, Takeuchi S, Nishimura M, Nagano T, Takekuma M, Shahzad MMK, Pejovic T, Omatsu K, Kelley JL, Ueland FR, Roman LD.
  Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
  J Surg Oncol. 2017 Oct 16. doi: 10.1002/jso.24861. [Epub ahead of print]
• Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K.
  The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.
  Oncoimmunology. 6(8): e1338996. doi: 10.1080/2162402X.2017.1338996. eCollection 2017.
• Yoshida H, Shintani D, Ogasawara A, Fujiwara K.
  Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancer.
  Arch Gynecol Obstet. 296(4): 819-26, 2017
• Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, Im DD, Bush SH, Ueda Y, Takano T, Blake EA, Hasegawa K, Baba T, Shida M, Satoh S, Yokoyama T, Machida H, Adachi S, Ikeda Y, Iwasaki K, Miyake TM, Yanai S, Nishimura M, Nagano T, Takekuma M, Takeuchi S, Pejovic T, Shahzad MM, Ueland FR, Kelley JL, Roman LD.
  Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
  Gynecol Oncol. 145(1): 78-87, 2017
• Ikeda Y, Kiyotani K, Yew PY, Sato S, Imai Y, Yamaguchi R, Miyano S, Fujiwara K, Hasegawa K, Nakamura Y.
  Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.
  Oncol Rep. 37(5): 2603-10, 2017
• Hanaoka T, Hasegawa K, Kato T, Sato S, Kurosaki A, Miyara A, Nagao S, Seki H, Yasuda M, Fujiwara K.
  Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
  Mol Diagn Ther. 21(2): 187-198, 2017
• Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K.
  Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
  Cancer Sci. 108(9): 1834-42, 2017
• Nishikawa T, Hasegawa K, Yabuno A, Yoshida H, Yasuda M, Kozawa E, Fujiwara K.
  Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.
  J Gynecol Oncol. 28(1): e25, 2017
• Iizumi S, Shimoi T, Nishikawa T, Kitano A, Sasada S, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.
  Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
  Intern Med 2017; 56: 2879-82, 2017
• Sugiyama T, Mizuno M, Aoki Y, Sakurai M, Nishikawa T, Ueda E, Tajima K, Takeshima N.
  A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.
  Jpn J Clin Oncol 47: 39-46, 2017
• Hirakawa A, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, Ueda T, Ozaki T, Tamura K, Kawai A, Fujiwara Y.
  Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan.
  Therapeutic Innovation & Regulatory Science: https://doi.org/10.1177/2168479017728989, 2017
• Sato S, Kato T, Abe K, Hanaoka T, Yano Y, Kurosaki A, Yasuda M, Sekino T, Fujiwara K, Hasegawa K.
  Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression.
  Oncol Lett. 14(1): 776-86, 2017
• Seto S, Itakura A, Okagaki R, Suzuki M, Ishihara O.
  An algorithm for the management of coagulopathy from postpartum hemorrhage, using fibrinogen concentrate as first-line therapy.
  Int J Obstet Anesth. 2017 Nov;32:11-16. doi: 10.1016/j.ijoa.2017.03.005. Epub 2017 Apr 1.
• Tochigi H, Kajihara T, Mizuno Y, Mizuno Y, Tamaru S, Kamei Y, Okazaki Y, Brosens JJ, Ishihara O.
  Loss of miR-542-3p enhances IGFBP-1 expression in decidualizing human endometrial stromal cells.
  Sci Rep. 2017 Jan 4;7:40001. doi: 10.1038/srep40001.
• Sultana S, Kajihara T, Mizuno Y, Sato T, Oguro T, Kimura M, Akita M, Ishihara O
  Overexpression of microRnA-542-3p attenuates the differentiating capacity of endometriotic stromal cells.
  Reprod Med Biol. 16(2):170-178, 2017

 邦　文

• 西川忠曉、長谷川幸清、新谷大輔、矢野友梨、佐藤　翔、藪野　彰、黒崎　亮、吉田裕之、藤原恵一
  婦人科がん化学療法に伴う末梢神経障害に対するプレガバリンおよびトラマドール併用の有用性
  癌と化学療法44(3): 227-31, 2017

論文総説

邦文

• 石原　理
  性同一性障害に対するホルモン療法
  内分泌・糖尿病・代謝内科44(1): 75-9, 2017 
• 石原　理
  女性化ホルモン療法の臨床と課題
  ホルモンと臨床　63(4):289-293, 2015 (2017発行) 
• 石原　理、瀬戸さち恵
  婦人科から見た性分化疾患
  思春期学35(3): 271-4, 2017
• 藤原恵一、青谷恵利子
  変化にどう対応するか　臨床研究法制化に対応する医師主導臨床研究グループの方向性
  腫瘍内科19(3): 359-63, 2017
• 藤原恵一
  進行卵巣、卵管、原発性腹膜がんに対する、パクリタキセル静脈内投与およびカルボプラチン腹腔内投与の併用療法
  ライフライン21がんの先進医療25: 22-5, 2017
• 藤原恵一
  CRCに求めるもの　医師の立場から
  薬理と治療45(8): 1227-9, 2017
• 藤原恵一
  婦人科がん領域における化学療法の現状と将来像 総括
  癌と化学療法44(2): 121-22, 2017.
• 亀井良政
  出生前診断としてのDNAマイクロアレイ
  臨床婦人科産科71(4): 78, 2017
• 亀井良政
  産科超音波のサイン　Nuchal translucency
  画像診断37(9): 954, 2017
• 亀井良政
  胎児評価Up To Date Integrated antenatal surveillanceについて
  腎と透析83(5): 753-6, 2017 
• 岡垣竜吾
  先天性子宮形態異常
  産科と婦人科84(2): 193-7, 2017 
• 永田一郎
  これだけはできるようになりたいPOP手術　1.経腟NTR「腟閉鎖術」
  日本女骨盤底医学会誌14(1):7-11, 2017 
• 難波　聡
  無月経
  臨床婦人科産科71(7): 620-5, 2017 
• 難波　聡
  異常な発汗
  周産期医学47(増刊号): 128-31, 2017 
• 髙橋幸子
  若年者に対する性虐待への対応
  臨床婦人科産科71(6): 553-7, 2017 
• 田丸俊輔
  周産期症例　妊娠中期(11)　腹腔内嚢胞を認めたときの鑑別診断のポイントは？
  臨床婦人科産科71(4): 89-93, 2017 
• 仲神宏子
  周産期症例　妊娠初期(4)
  臨床婦人科産科71(4): 23-6, 2017 
• 西川忠曉、米盛　勧
  希少がん治療のエビデンス創出に向けての国立がん研究センターの取り組み
  血液内科74(4): 545-50, 2017 
• 西川忠曉、米盛　勧
  薬物療法にはどのような治療がありますか
  Medicina 54(8): 1196-9, 2017 
• 西川忠曉、大熊ひとみ、田村研治
  PARP阻害薬
  がん分子標的治療 15(4): 56(408)-61(413), 2017